Literature DB >> 20406936

Clinical relevance of conditional survival of cancer patients in europe: age-specific analyses of 13 cancers.

Maryska L G Janssen-Heijnen1, Adam Gondos, Freddie Bray, Timo Hakulinen, David H Brewster, Hermann Brenner, Jan-Willem W Coebergh.   

Abstract

PURPOSE: When cancer survivors wish to receive accurate information on their current prognosis during follow-up, conditional 5-year relative survival may be most suitable. We have estimated conditional 5-year relative survival for 13 cancers using a large European database-European Network for Indicators on Cancer (EUNICE)-of 10 dedicated long-standing cancer registries across Europe. PATIENTS AND METHODS: Patients age 15 years and older diagnosed between 1985 and 2004 were included. Conditional 5-year relative survival for each age group was computed for every additional year survived up to 10 years. Period analysis with follow-up period 2000 to 2004 was used.
RESULTS: All patients with cutaneous melanoma or colorectal, endometrial, or testis cancer and younger patients with stomach, glottis, cervix, ovary, or thyroid cancer or non-Hodgkin's lymphoma exhibited hardly any excess mortality (conditional 5-year relative survival > 95%) given that they were alive at a defined time point within 10 years of initial diagnosis. However, patients with supraglottis, lung, breast, and kidney cancer, as well as older patients with most cancers exhibited substantial excess mortality (conditional 5-year relative survival < 90%). Initial differences in relative survival at diagnosis between age groups largely disappeared with time since initial diagnosis for melanoma, or stomach, colorectal, corpus uteri, or testicular cancer but persisted for patients diagnosed with other tumors. Differences between stage groups became smaller over time or disappeared.
CONCLUSION: Conditional relative survival shows clinically relevant variations according to time since diagnosis, type of cancer, and age, and can help serve as a guide for cancer survivors in planning for their future and for doctors in planning schedules for surveillance.

Entities:  

Mesh:

Year:  2010        PMID: 20406936     DOI: 10.1200/JCO.2009.25.9697

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  55 in total

1.  Updating survival estimates in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) based on treatment-free interval length.

Authors:  Eric M Ammann; Tait D Shanafelt; Kara B Wright; Bradley D McDowell; Brian K Link; Elizabeth A Chrischilles
Journal:  Leuk Lymphoma       Date:  2017-07-18

2.  Bladder cancer: Conditional survival after radical cystectomy.

Authors:  Giorgio Gandaglia; Maxine Sun
Journal:  Nat Rev Urol       Date:  2013-12-17       Impact factor: 14.432

3.  Actual prognosis during follow-up of survivors of B-cell non-Hodgkin lymphoma in the Netherlands.

Authors:  Saskia A M van de Schans; Liza N van Steenbergen; Jan Willem W Coebergh; Maryska L G Janssen-Heijnen; Dick Johan van Spronsen
Journal:  Haematologica       Date:  2013-09-13       Impact factor: 9.941

4.  Geriatric oncology: an overview of progresses and challenges.

Authors:  Martine Extermann
Journal:  Cancer Res Treat       Date:  2010-06-30       Impact factor: 4.679

5.  Implications of age and conditional survival estimates for patients with melanoma.

Authors:  Mousumi Banerjee; Christopher D Lao; Lauren M Wancata; Daniel G Muenz; Megan R Haymart; Sandra L Wong
Journal:  Melanoma Res       Date:  2016-02       Impact factor: 3.599

6.  Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors.

Authors:  Koji Sasaki; Hagop M Kantarjian; Preetesh Jain; Elias J Jabbour; Farhad Ravandi; Marina Konopleva; Gautam Borthakur; Koichi Takahashi; Naveen Pemmaraju; Naval Daver; Sherry A Pierce; Susan M O'Brien; Jorge E Cortes
Journal:  Cancer       Date:  2015-10-19       Impact factor: 6.860

7.  On the need for comprehensive assessment of impact of comorbidity in elderly patients with head and neck cancer.

Authors:  Afshin Teymoortash; Gyorgy B Halmos; Carl E Silver; Primož Strojan; Missak Haigentz; Alessandra Rinaldo; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-07-25       Impact factor: 2.503

8.  Conditional survival in patients treated with vascular endothelial growth factor-targeted therapy for advanced renal cell carcinoma.

Authors:  Y Zhu; Y P Hong; H L Zhang; G H Shi; W J Xiao; Z H Wang; X D Yao; S L Zhang; B Dai; D W Ye
Journal:  J Cancer Res Clin Oncol       Date:  2012-06-29       Impact factor: 4.553

9.  An interactive tool for individualized estimation of conditional survival in rectal cancer.

Authors:  Samuel J Wang; Amanda R Wissel; Join Y Luh; C David Fuller; Jayashree Kalpathy-Cramer; Charles R Thomas
Journal:  Ann Surg Oncol       Date:  2011-01-05       Impact factor: 5.344

10.  Quantifying fatigue in (long-term) colorectal cancer survivors: a study from the population-based patient reported outcomes following initial treatment and long term evaluation of survivorship registry.

Authors:  Melissa S Y Thong; Floortje Mols; Xin S Wang; Valery E P P Lemmens; Tineke J Smilde; Lonneke V van de Poll-Franse
Journal:  Eur J Cancer       Date:  2013-03-01       Impact factor: 9.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.